SCHEMBL1777934

SCHEMBL1777934

Cc1cccc(C)c1NC(=O)CN1CCNCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
DRD4 P21917 1/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
POLB P06746 1/20 0.54
KCNH2 Q12809 3/20 0.53
CHRM3 P20309 2/20 0.53
ADRB1 P08588 2/20 0.53
CYP3A4 P08684 2/20 0.53
ADRA2A P08913 2/20 0.53
CYP2D6 P10635 2/20 0.53
ADRA2B P18089 2/20 0.53
ADRA2C P18825 2/20 0.53
ADRA1A P35348 2/20 0.53
DRD3 P35462 2/20 0.53
HTR2B P41595 2/20 0.53
LMNA P02545 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C9 P11712 2/20 0.53
MLNR O43193 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8554173 0.97 ALDH1A1 (0.55) ALDH1A1DRD4MEN1KMT2APOLB
SCHEMBL1778375 0.91 ALDH1A1 (0.49) ALDH1A1DRD4MEN1KMT2APOLB
SCHEMBL9031046 0.91 DRD4 (0.60) ALDH1A1DRD4MEN1KMT2APOLB
SCHEMBL2327539 0.89 ALDH1A1 (0.64) ALDH1A1DRD4MEN1KMT2APOLB
Pyrrocaine SCHEMBL25718 0.86 MEN1 (0.70) ALDH1A1DRD4MEN1KMT2APOLB
SCHEMBL4034304 0.86 TP53 (0.56) ALDH1A1MEN1KMT2AKCNH2CYP1A2
SCHEMBL7288776 0.85 POLB (0.74) ALDH1A1MEN1KMT2APOLBCHRM3
SCHEMBL2096761 0.85 MEN1 (0.73) ALDH1A1DRD4MEN1KMT2APOLB
SCHEMBL22407740 0.85 MEN1 (0.73) ALDH1A1DRD4MEN1KMT2APOLB
Pincainide SCHEMBL2110148 0.85 MEN1 (0.73) ALDH1A1DRD4MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103664829-A Ranolazine synthesis technology CHENGDU YILUKANG MEDICAL TECHNOLOGY & SERVICE CO LTD 2014-03-26 CN claimed
CN-103570645-A Method for preparing N-(2,6-dimethyl phenyl)-2-(1-piperazine)acetamide SHANGHAI DESANO CHEMICAL PHARM 2014-02-12 CN claimed
US-8541578-B2 Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide JANSSEN PHARMACEUTICA, N.V. (BE) 2013-09-24 US claimed
EP-2586774-A1 METHOD FOR PREPARATION OF RANOLAZINE Shanghai Kuoikee Laboratories Co., Ltd (CN) 2013-05-01 EP claimed
CN-102367241-B Preparation method of ranolazine QILU TIANHE PHARMACEUTICAL CO LTD 2013-04-17 CN claimed
US-20130090475-A1 Process for the Preparation of Ranolazine ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) 2013-04-11 US claimed
US-20110223213-A1 HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2011-09-15 US claimed
EP-2356097-A2 HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group PTC ehf. (IS) 2011-08-17 EP claimed
US-20110151258-A1 PREPARATION OF RANOLAZINE DR. REDDY'S LABORATORIES LTD. (IN) 2011-06-23 US claimed
EP-2328873-A2 PREPARATION OF RANOLAZINE Dr. Reddy's Laboratories Ltd. (IN) 2011-06-08 EP claimed
WO-2010043976-A2 HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-04-22 WO claimed
WO-2010023687-A2 PREPARATION OF RANOLAZINE, ITS SALTS AND INTERMEDIATES THEREOF SHODHANA LABORATORIES LIMITED (IN) 2010-03-04 WO claimed
WO-2010025370-A2 PREPARATION OF RANOLAZINE DR. REDDY'S LABORATORIES LTD. (IN) 2010-03-04 WO claimed
CN-100494187-C Method for synthesizing Ranolazine JIE YAN (CN) 2009-06-03 CN claimed
EP-1517900-B1 PROCESS FOR THE PRODUCTION OF N-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE JANSSEN PHARMACEUTICA NV (BE) 2009-05-27 EP claimed
WO-2008047388-A2 IMPROVED PROCESS FOR THE PREPARATION OF RANOLAZINE IND-SWIFT LABORATORIES LIMITED (IN) 2008-04-24 WO claimed
CN-1915982-A Method for synthesizing Ranolazine YAN JIE (CN) 2007-02-21 CN claimed
US-20050240018-A1 Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide JANSSEN PHARMACEUTICA, N.V. (BE) 2005-10-27 US claimed
EP-1517900-A1 PROCESS FOR THE PRODUCTION OF N-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE JANSSEN PHARMACEUTICA N.V. (BE) 2005-03-30 EP claimed
WO-2004000824-A1 PROCESS FOR THE PRODUCTION OF N-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE JANSSEN PHARMACEUTICA N.V. (BE) 2003-12-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110223213-A1 HIGHLY PURE RANOLAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF REN, ADRB3, RAN ALDH1A1 2045/4885DRD4 1176/4885MEN1 4060/4885
US-20130090475-A1 Process for the Preparation of Ranolazine RANBP1, RANBP2, RAN ALDH1A1 279/4885DRD4 2063/4885MEN1 3207/4885
US-20050240018-A1 Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide SCN5A, SCN2A, NAA15 ALDH1A1 1020/4885DRD4 1230/4885MEN1 4527/4885
US-20110151258-A1 PREPARATION OF RANOLAZINE RANBP1, RAN, ACHE ALDH1A1 949/4885DRD4 602/4885MEN1 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.